Navigation Links
Progen Pharmaceuticals Announces Fiscal 2007 Financial Results

- Positive Phase 2 Clinical Trial Results from PI-88 in Liver Cancer and

$92.4 million in Raised Capital Highlight the Year -

SYDNEY, Australia, Aug. 23 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today released its financial results for the fiscal year ended 30 June 2007.

Fiscal 2007 Corporate Highlights

* Announced positive results from a Phase 2, 172 patient, post-resection

liver cancer trial for P1-88 that support moving into a multi-national

registration-directed Phase 3 trial;

* Raised a net total of $92.4 million through various fundraising

activities, which provides Progen with additional working capital to fund

the Phase 3 clinical development of PI-88 in post-resection liver cancer,

conduct additional clinical trials of PI-88 in other indications and

further develop other product candidates;

* Completed a royalty-buy-back negotiation with Medigen Biotechnology

Corporation (Medigen) resulting in the conclusion of the Strategic

Alliance between the two companies, which provides Progen with maximum

flexibility and the opportunity to more rapidly develop and commercialise


* Continued efforts on the Company's Phase 2 PI-88 prostate and melanoma

trials with results expected in the first half and second half of calendar

2008, respectively;

* Completed Phase 2 Non-Small Cell Lung Cancer trial with results due by

the end of the third quarter in calendar 2007;

* Received a grant of up to $4.6 million through the Australian

Government's Pharmaceuticals Partnerships Program that will be used

towards PI-88's research and development costs;

* Expanded senior management team and established leading international

clinical advisory board of liver cancer specialists to support the

clinical development and commercialisation of PI-88 in post-resection

liver cancer;

* Selected lead candidates for our drug discovery program focused on

developing inhibitors of heparin binding proteins, and presented animal

data at the American Association of Cancer Research meeting. Progen

expects to submit an Investigational New Drug application to the FDA by

the end of the calendar year 2008.

"This past fiscal year was the most significant and successful in Progen's history," said Justus Homburg, Chief Executive Officer of Progen Pharmaceuticals. "Our positive Phase 2 results for PI-88 in liver cancer, combined with our considerable fundraising efforts, have effectively positioned us to initiate our Phase 3 Trial during this calendar year and continue aggressively pursuing the development, registration and commercialisation of PI-88. At the completion of the trial, we expect to have a registration package for PI-88 in over a dozen countries."

Fiscal 2007 Financial Results:

Progen's operating loss for the year ended 30 June 2007 was $22.5 million, as compared to $7.6 million in 2006. The operating loss from continuing operations, excluding the non-recurring compensation of $11.7 million paid to Medigen in 2007, amounted to $10.7 million, as compared to $7.0 million in 2006, representing a 53.6 percent increase from last year. Of the $11.7 million paid to Medigen, $11.4 million was non-cash and included equity payments and the return of our investment in Medigen.

The operating loss includes expenses of $2.2 million, as compared to $369,000 in 2006 for costs associated with preparations for the Phase 3 development of PI-88, including regulatory, additional animal studies and manufacturing.

Fiscal 2007 revenue and other income totalled $3.8 million, as compared to $2.8 million in 2006, a 33.9 percent increase. This increase was due to a 41.2 percent increase in revenue from a previously received Australian government grant, and a 58.3 percent increase in interest income due to increased funds on deposit following the Company's capital raisings.

* All figures quoted above are in Australian dollars.

About Progen: Progen Pharmaceuticals Limited is an Australian-based globally focused biotechnology company committed to the discovery, development and commercialisation of small molecule therapeutics primarily for the treatment of cancer.

Progen Information:

Linton Burns

Progen Pharmaceuticals Limited

T: +61 7 3842 3333


Noreen Dillane

Progen Pharmaceuticals Limited

T: +61 7 3842 3333


Media and Investor Relations Australia:

Rebecca Piercy

Buchan Consulting

T: +61 2 9237 2800 / 0422 916 422


Rebecca Wilson

Buchan Consulting

T: +61 417 382 391


Media Relations USA:

Robert D. Stanislaro


T: 212-850-5657


Investor Relations USA:

Evan Smith


T: 212-850-5606


SOURCE Progen Pharmaceuticals Limited
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Progenics Announces Positive Results in Clinical Trial of Novel HIV Therapy
3. Progens Phase 2 Liver Cancer Trial Exceeds Efficacy Objective
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
10. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Cell Surface Marker ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/25/2015)...  Amgen (NASDAQ: AMGN ) today announced the ... the United States (U.S.) Food and ... to Humira ® (adalimumab). Amgen believes this submission ... FDA and represents Amgen,s first BLA submission using the ... M.D., executive vice president of Research and Development at ...
(Date:11/25/2015)... 25, 2015 AAIPharma Services Corp./Cambridge Major ... at least $15.8  Million to expand its laboratories ... . The expansion will provide additional office ... growing demands of the pharmaceutical and biotechnology markets. ... will provide up to 40,000 square feet of ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... ... EST until 11:59 p.m. EST, customers will be racing the clock to ... or more to free gifts with purchases, there will be a new sale available on ... skin care and cosmetic needs, customers will save on already discounted prices. , Top brands ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... According to ... are not changing the way that they are handling security in light of the ... and security presence in an attempt to stop an attack from reaching U.S. soil. ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced ... offering customers 10% off of their purchase of lice treatment product. In addition, customers ... According to a company spokesperson. “Finding lice is a sure way to ruin the ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions announced today ... Group (MSDSLUG). Recognized as Microsoft’s official group for end users of Dynamics SL ... users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates their ongoing ...
(Date:11/27/2015)... ... 2015 , ... The men and women on this list ... the country. They have overseen financial turnarounds, shown commitment to their community through ... as a whole through their advocacy and professional efforts. , Becker's Hospital Review ...
Breaking Medicine News(10 mins):